PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if treatment with PLX3397 and Sirolimus will be
tolerated and result in shrinking of the cancer or stopping the cancer from growing. In the
phase I portion, the maximum tolerate dose of the study drug will be determined. In the Phase
II portion, progression free survival will be assessed at the dose level found in Phase I.
Participants will continue to take the study drug until they experience an unacceptable side
effect or their disease progresses. Funding Source - FDA OOPD